Neo Ivy Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Neo Ivy Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.45M	Buy	+43,355	New	+$2.53M	0.65%	55
2025 Q3	–	Sell	-5,254	Closed	-$289K	–	398
2025 Q2	$289K	Sell	5,254 -19,834	-79%	-$1.17M	0.09%	252
2025 Q1	$1.77M	Buy	+25,088	New	+$1.69M	0.56%	77
2024 Q4	–	Sell	-21,020	Closed	-$1.48M	–	280
2024 Q3	$1.48M	Buy	21,020 +20,116	+2,225%	+$1.68M	0.48%	85
2024 Q2	$74K	Buy	+904	New	+$75.3K	0.01%	211
2022 Q4	–	Sell	-798	Closed	-$68K	–	345
2022 Q3	$68K	Buy	798 +55	+7%	+$4.9K	0.18%	189
2022 Q2	$61K	Buy	+743	New	+$59.2K	0.16%	208
2021 Q4	–	Sell	-1,044	Closed	-$129K	–	448
2021 Q3	$129K	Buy	+1,044	New	+$82.4K	0.15%	212
2021 Q2	–	Sell	-505	Closed	-$38K	–	456
2021 Q1	$38K	Sell	505 -182	-26%	-$14.9K	0.04%	355
2020 Q4	$60K	Buy	+687	New	+$54.5K	0.07%	293
2020 Q3	–	Sell	-1,044	Closed	-$129K	–	471
2020 Q2	$129K	Buy	1,044 +688	+193%	+$68.4K	0.15%	212
2020 Q1	$30K	Buy	+356	New	+$30.7K	0.05%	352
2019 Q3	–	Sell	-3,527	Closed	-$302K	–	292
2019 Q2	$302K	Buy	+3,527	New	+$302K	0.17%	187

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neo Ivy Capital Management's BMRN Position: Q1 2026 in Review

Neo Ivy Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 43,355 shares worth $2.45M. The stake represents 0.65% of the portfolio and ranks #55 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in BMRN as recently as Q2 2025.

Neo Ivy Capital Management first reported a position in BMRN in Q2 2019 and has held it in 13 quarters since. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Neo Ivy Capital Management held 43,355 shares of BioMarin Pharmaceuticals worth $2.45M as of Q1 2026.
BioMarin Pharmaceuticals was a new Neo Ivy Capital Management position in Q1 2026.
BioMarin Pharmaceuticals made up 0.65% of Neo Ivy Capital Management's portfolio in Q1 2026, its #55 holding.
Neo Ivy Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 13 quarters since.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.